业界动态国内医卫资讯
FDA批准Pimicotinib用于症状性TGCT
Medscape News · 2026-11-11 03:29
摘要
Serono公司表示,其CSF-1R抑制剂在3期试验中客观缓解率最高,有望成为“同类最佳”。Medscape Medical News
English
FDA Approves Pimicotinib for Symptomatic TGCT
With the highest objective response rate in a phase 3 trial, Serono says its CSF-1R inhibitor is a potential 'best-in-class.' Medscape Medical News